FUS Antibody

Knockout Validated: FUS Antibody [NB100-565] - Western blot shows lysates of HEK293 human embryonic kidney parental cell line and FUS knockout (KO) HEK293 human embryonic kidney cell line. PVDF membrane was probed with 1:1000 of Rabbit Anti-Human FUS Polyclonal Antibody (Catalog # NB100-565) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for FUS at approximately 75 kDa (as indicated) in the parental HEK293 celll line, but is not detectable in the knockout HEK293 cell line. This experiment was conducted under reducing conditions.

Western Blot: FUS Antibody [NB100-565] - FUS activates GSK-3beta in transfected cells and transgenic mice A. Cells were transfected with either control vector (CTRL), HA-FUS, HA-FUSR521C or HA FUSR518K and the samples probed on immunoblots for GSK-3beta phosphorylated on serine 9 (GSK-3beta-S9), total GSK-3beta, FUS (using FUS antibody) and tubulin as a loading control. Phosphorylation of GSK-3beta serine 9 is the principal mechanism for regulating its activity; serine 9 phosphorylation inhibits GSK-3beta activity. Bar chart shows relative levels of GSK-3beta serine 9 phosphorylation following quantification of signals from immunoblots and normalization to total GSK-3beta signals. Data were analysed by one-way ANOVA and Tukey's post hoc test. N = 4, error bars are s.e.m.; *P < 0.05. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/10.15252/embr.201541726), licensed under a CC-BY licence.

Immunocytochemistry/Immunofluorescence: FUS Antibody [NB100-565] - FUS (NB100-565) (green), b-III Tubulin (white), DAPI (blue). FUS antibody dilution: 1:300 in PBST (0.1% Triton X-100) + 10% GS O/N 4C. ICC/IF image submitted by a verified customer review.

Immunohistochemistry-Paraffin: FUS Antibody [NB100-565] - FFPE section of mouse renal cells carcinoma. Affinity purified rabbit anti-FUS used at a dilution of 1:1,000 (1 ug/mL). Detection: DA

Western Blot: FUS Antibody [NB100-565] - Whole cell lysate (50 ug) from HepG2, HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Affinity purified rabbit anti-FUS antibody used for WB at 0.04 ug/mL. Detection: chemiluminescence with an exposure time of 10 seconds.

Immunohistochemistry-Paraffin: FUS Antibody [NB100-565] - FFPE section of human ovarian carcinoma. Affinity purified rabbit anti-FUS used at a dilution of 1:1,000 (1 ug/mL). Detection: DAB

Immunoprecipitation: FUS Antibody [NB100-565] - Detection of human FUS by Western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-FUS antibody NB100-565 used for IP at 3 ug per reaction. FUS was also immunoprecipitated by rabbit anti-FUS recombinant monoclonal antibody [BLR023E] (NBP2-76415) and rabbit anti-FUS antibody NB100-561. For blotting immunoprecipitated FUS, NB100-565 was used at 1:1000. Detection: Chemiluminescence with an exposure time time of 3 minutes.

• Reactivity: Hu, Mu, Rt, Bv
• Applications: WB, ICC/IF, IHC, IHC-P, IP, KO
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: 1.0 mg/ml

FUS Antibody Summary

• Immunogen: The immunogen recognized by this antibody maps to a region between residues 1 and 50 of human fusion (involved in t(12;16) in malignant liposarcoma) using the numbering given in SwissProt entry P35637 (GeneID 2521).
• Predicted Species: Bovine (100%). Backed by our 100% Guarantee.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: FUS
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/Immunofluorescence 1:500 - 1:2000
  • Immunohistochemistry 1:500 - 1:2000
  • Immunohistochemistry-Paraffin 1:500 - 1:2000
  • Immunoprecipitation 2-10 ug/mg lysate
  • Knockout Validated
  • Western Blot 1:2000 - 1:10000
• Application Notes: Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections. ICC/IF reactivity reported in scientific literature (PMID: 28444573). FUS antibody validated for ICC/IF from a verified customer review.
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  FUS Overexpression Lysate

Reactivity Notes

Rat reactivity reported in scientific literature (PMID: 26403203).

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: Tris-Citrate/Phosphate (pH 7.0 - 8.0)
• Preservative: 0.09% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for FUS Antibody

• 75 kDa DNA-pairing protein
• ALS6
• amyotrophic lateral sclerosis 6
• FUS1
• fused in sarcoma
• fusion (involved in t(12;16) in malignant liposarcoma)
• fusion gene in myxoid liposarcoma
• fusion, derived from t(12;16) malignant liposarcoma
• fus-like protein
• heterogeneous nuclear ribonucleoprotein P2
• HNRNPP2
• Oncogene FUS
• Oncogene TLS
• POMP75
• RNA-binding protein FUS
• TLShnRNP-P2
• Translocated in liposarcoma protein

Background

FUS is a nucleic acid-binding protein whose N-terminal half functions as a transcriptional activator domain in fusion oncoproteins found in human leukemias and liposarcomas. FUS has been reported to be associated with the nuclear matrix and has been implicated in transcription, pre-mRNA splicing processes, spliceosome assembly, and promoting undifferentiated endothelial cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for FUS Antibody (NB100-565)(24)

Publications using NB100-565

• Tavares M, Khandelwal G, Muter J et al. JAZF1-SUZ12 dysregulates PRC2 function and gene expression during cell differentiation Cell reports 2022-05-31 [PMID: 35649353] (WB, Mouse)
• Devoy A, Price G, De Giorgio F Et al. Generation and analysis of innovative genomically humanized knockin SOD1, TARDBP (TDP-43), and FUS mouse models iScience 2021-12-01 [PMID: 34988393] (IHC, Human)
• Chennampally P, Sayed-Zahid A, Soundararajan P et al. A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin Scientific reports 2021-09-13 [PMID: 34518579] (ICC/IF, WB)
• Skalska L, Begley V, Beltran M et al. Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin Molecular cell 2021-06-17 [PMID: 34166609]
• van den Berk P, Lancini C, Company C et al. USP15 Deubiquitinase Safeguards Hematopoiesis and Genome Integrity in Hematopoietic Stem Cells and Leukemia Cells Cell reports 2020-12-29 [PMID: 33378683] (WB, Human)
• Vakil PR PARP-1 Activation Directs FUS to DNA Damage Sites to Form PARG-Reversible Compartments Enriched in Damaged DNA Cell Rep 2019-05-07 [PMID: 31067465]
• Martinez-Macias MI, Moore DA, Green RL et al. FUS (fused in sarcoma) is a component of the cellular response to topoisomerase I-induced DNA breakage and transcriptional stress Life Sci Alliance 2019-04-01 [PMID: 30808650] (ICC/IF, Human)
• Gittings LM, Foti SC, Benson BC et al. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS Acta Neuropathol Commun. 2019-02-11 [PMID: 30755280] (IHC-P, Human)
• Pansarasa O, Bordoni M, Dufruca L, Diamanti L. ALS lymphoblastoid cell lines as a considerable model to understand disease mechanisms. Dis Model Mech. 2018-01-29 [PMID: 29419416] (Human)
• Prpar Mihevc S, Pavlin M, Darovic S et al. Modelling FUS Mislocalisation in an In Vitro Model of Innervated Human Muscle J. Mol. Neurosci. 2017-06-15 [PMID: 28620838] (IHC-P, Human)
• Lojk J, Prpar Mihevc S, Bregar VB et al. The Effect of Different Types of Nanoparticles on FUS and TDP-43 Solubility and Subcellular Localization. Neurotox Res. 2017-04-25 [PMID: 28444573] (ICC/IF)
• Gami-Patel P, Bandopadhyay R, Brelstaff J et al. The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS positive inclusions Neurobiology of Aging 2016-07-15 [PMID: 27500866] (IHC, WB, Human)
• Stoica R, Paillusson S, Gomez-Suaga P et al. ALS/FTD-associated FUS activates GSK-3 Beta to disrupt the VAPB-PTPIP51 interaction and ER-mitochondria associations EMBO Rep. 2016-07-14 [PMID: 27418313]
• Darovic S, Prpar Mihevc S et al. Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import. J Cell Sci 2015-11-15 [PMID: 26403203] (IP, Human)
• Sibley CR, Emmett W, Blazquez L et al. Recursive splicing in long vertebrate genes. Nature. 2015-05-21 [PMID: 25970246] (Human)
• Rogelj B, Easton LE, Bogu GK et al. Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain Sci Rep 2012-01-01 [PMID: 22934129] (IP, Mouse)
• Suzuki N, Kato S, Kato M et al. FUS/TLS-immunoreactive neuronal and glial cell inclusions increase with disease duration in familial amyotrophic lateral sclerosis with an R521C FUS/TLS mutation. J Neuropathol Exp Neurol 2012-09-01 [PMID: 22878663]
• Ghazi-Noori S, Froud KE, Mizielinska S et al. Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain. 2012-03-01 [PMID: 22366797] (IHC, Mouse)
• Ahmed Z, Doherty KM, Silveira-Moriyama L et al. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies Acta Neuropathol 2011-10-01 [PMID: 21773886] (IHC, Human)
• Lashley T, Rohrer JD, Bandopadhyay R et al. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011-09-01 [PMID: 21752791] (Human)
• Lanson NA Jr, Maltare A, King H et al. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum Mol Genet 2011-07-01 [PMID: 21487023]
• Kino Y, Washizu C, Aquilanti E et al. Intracellular localization and splicing regulation of FUS/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations. Nucleic Acids Res 2011-04-01 [PMID: 21109527]
• Mackenzie IR, Munoz DG, Kusaka H et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol 2011-02-01 [PMID: 21052700]
• Neumann M, Rademakers R, Roeber S et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 2009-11-01 [PMID: 19674978]

Reviews for FUS Antibody (NB100-565) (4)

Average Rating: 5

(Based on 4 reviews)

We have 4 reviews tested in 2 species: Human, Mouse.

reviewed by: Marina Villar WB Human 10/31/2020

Summary

• Application: Western Blot
• Sample Tested: Human primary fibroblast
• Species: Human
• Lot: A4

Comments

• Comments: Primary antibody incubation: 1:1000 in 5% Milk in PBST (0.1% Tween) O/N 4ºC. Secondary antibody incubation: 1:5000 1h RT Goat anti-rabbit HRP. ECL+. 1s exposure.

reviewed by: Marina Villar ICC Mouse 02/19/2020

Summary

• Application: Immunocytochemistry
• Sample Tested: Cortical neurons
• Species: Mouse
• Lot: A4

Comments

• Comments: FUS ab dilution: 1:300 in PBST (0.1% triton) + 10% GS O/N 4ºC.

reviewed by: Yichi Xu WB Human 01/30/2019

Summary

• Application: Western Blot
• Sample Tested: cell
• Species: Human
• Lot: A-3

Comments

• Comments: At least more than 20 μg sample is optimal.

reviewed by: Verified Customer IF Human 10/15/2013

Summary

• Application: Immunofluorescence
• Sample Tested: HeLa cells
• Species: Human
• Lot: A1

Bioinformatics

• Gene Symbol: FUS
• Entrez:
  • 2521(Human)
  • 233908(Mouse)
• Uniprot:
  • P35637(Human)